Category Archives: Health: Addiction

Addiction one of the Largest growing Problem’s in the world today. This Press Release Service will bring you the newest services and research available.

Slim Pickings: Finding Cost-Effective Obesity Solutions


A shift to office work has reduced our energy use. Technology advances, automation, urbanization, cars and other energy-saving changes have also contributed. During the 1960s, half of all jobs required moderate intensity physical energy expenditure, whereas in 2010, fewer than 20% did.

Trends in Obesity: 1963 to 2018 (CDC)

Corpulent Costs

Obesity not only increases health risks and reduces quality of life and mobility; but also produces a significant economic impact. Two primary drivers behind this cost burden include medical care and productivity.

A 2021 study found that obese adults were burdened with medical costs $2,505 greater than individuals of normal weight. It found that obese individuals covered by public health insurance programs incurred more costs than average, adding $2,868 per year. Overall health care costs attributed to obesity in the United States were an estimated $261 billion in 2018 and 2.2% of gross domestic product in 2019.

Annual Health Spending: Obese vs. Not

Obesity is associated with lower work productivity and absenteeism. Research has identified material health-related productivity losses. Obese workers are overall less likely to be employed and suffer from other challenges that impair work efficiency. There is also an association between obesity and reduced motivation. Depression, poor self-image, loss of enjoyment and other related factors are all more common in obese persons compared to normal-weight counterparts.

Obesity Death Rate/100,000 Individuals (IHME)

Reclaiming the Spotlight

The search for an effective weight loss product has followed a winding path throughout the decades. Regulators have added and deleted products based on developing information. However, the rapidly-growing obese population demands robust solutions.

Glucagon-like peptide (GLP-1) agonists were first approved for Type 2 diabetes in 2005. They stimulate insulin production and inhibit glucagon release from the pancreas. GLP-1s also delay gastric emptying, which limits blood sugar volatility. Other GLP-1 agonists were later approved to address type 2 diabetes including semaglutide, liraglutide and dulaglutide. Researchers found that GLP-1 patients reduced food intake and lost weight. This led to additional studies and the 2014 approval of liraglutide for weight loss; however, its effectiveness was mediocre. In 2021, semaglutide (Wegovy) produced better outcomes, generating impressive results in a clinical study, angling the spotlight towards weight loss and GLP-1s. A recent Goldman Sachs report estimates the market could reach $100 billion by 2030.

Obesity Treatment

The first prescription to achieve weight loss is a change in diet and exercise. Avoiding high-sugar foods and consuming fresh fruits and vegetables are other interventions. Evidence shows regular physical activity can also be an effective complement.

For many, medicines may be necessary as diet and exercise are not enough. These are generally recommended for people with a BMI over 30 (obesity) or a BMI over 27 (overweight) with weight-related health conditions like diabetes or hypertension.

While the weight loss benefits of GLP-1s have attracted the eye of dieters, so has their burdensome price which can range from $800 to $1,350 per month. Except for the occasional billionaire, most patients are not able to afford the product without insurance. And many insurers have been reducing coverage due to cost. Combined with the shortage of GLP-1s, the need for alternatives becomes clear.

While recent interest in GLP-1 agonists such as Wegovy and Zepbound has rallied interest in the whole group and captured the limelight, there are many therapeutics available. Other prominent options include orlistat, phentermine hydrochloride & topiramate, and deoxycholic acid.

A literature review by Mital and Nguyen [1] found that, of the four leading anti-obesity drugs approved for pediatric use, phentermine-topiramate (Qsymia) was most cost effective. All [2] demonstrated similar, mild to moderate, adverse events. Of the four, only Qsymia generated an incremental cost effectiveness ratio (ICER) under payors’ standard threshold. Over a 30-year horizon Qsymia’s ICER advantage was even greater.

Weight Loss Medications

Summary

There is much to consider when addressing obesity. The health risks are well documented and can dramatically affect quality of life and wealth. While obesity’s solution is sometimes simplified to exercise and diet, these are frequently inadequate and further intervention is needed. Surgery or medications can help achieve weight loss but bear significant costs and side effects which must be balanced against outcomes. With the additional healthcare burden of obesity exceeding thousands of dollars per year, a balance between treatment cost and benefit is needed. This requires alternative approaches and comprehensive efforts that combine cost-effective medications with diet and exercise to reduce excessive obesity rates.

Extended version of article here with references.

[1] Mital, S., Nguyen, H. Cost-Effectiveness of Anti-obesity Drugs for Adolescents With Severe Obesity. JAMA Network. October 2023.

[2] Other medicines: orlistat, liraglutide & semaglutide

Media Contact

John Vandermosten, Unboxing Biotech, 1 (240) 778-4204, [email protected], unboxingbiotech.com

SOURCE Unboxing Biotech

Veterans Exploring Treatment Solutions (VETS) Grant Recipients Participate in Groundbreaking Stanford Study on Ibogaine Treatment for PTSD and TBI


First-ever study of ibogaine treatment for TBI reveals reduced symptoms and improved functioning

CORONADO, Calif., Jan. 5, 2024 /PRNewswire-PRWeb/ — Veterans Exploring Treatment Solutions (VETS), a leading non-profit organization dedicated to ending veteran suicide, shares the findings of a new groundbreaking study that it supported alongside Stanford University. The study, published today in Nature Medicine, is the first-of-its-kind observational study that captured the effects of ibogaine, the plant-based psychoactive drug, on veterans with Traumatic Brain Injury (TBI) and the debilitating consequences, including Post Traumatic Stress Disorder (PTSD).

The study demonstrated that prior to ibogaine treatment, participants scored an average of 30.2 on the World Health Organization Disability Assessment Schedule 2.0, equivalent to mild to moderate disability. At one month following ibogaine treatment, the average rating improved to 5.1, equivalent to no disability. The researchers also found a statistically significant reduction in suicidal ideation from participants, decreasing from 47% to 7% one month following treatment. The participants experienced no serious side effects or heart complications resulting from the ibogaine treatment.

The paper, authored by Dr. Nolan Williams, Associate Professor in the Department of Psychiatry and Behavioral Sciences and the Director of the Brain Stimulation Lab at Stanford University, indicates that ibogaine, combined with a cardioprotective agent, effectively treated TBI in Special Operations veterans. Researchers enrolled 30 U.S. Special Operations veterans in the study, all of whom had received Foundational Healing Grants from VETS for travel support and ibogaine therapy. The study revealed that ibogaine therapy significantly reduced PTSD, anxiety, depression, and improved cognitive function in veterans with TBI.

“Veterans are on the front line of our national defense, but here they are on the front line of cutting-edge research that has the potential to help millions of people – both in and out of uniform,” said Amber Capone, Co-Founder and CEO of VETS. “We remain laser-focused and dedicated to our mission of supporting access to psychedelic-assisted therapies for veterans and advancing research into their safety and efficacy. Our collaboration with Stanford University and Dr. Williams is a major step forward in proving the potential of ibogaine for treating PTSD and TBI.”

Since its inception in 2019, VETS has been at the forefront of combating veteran suicide by providing resources, research, and advocacy efforts for veterans and veteran spouses seeking psychedelic-assisted therapies for PTSD, TBI, and other mental health conditions. The 30 participants selected had a history of TBI and repeated blast exposures and were experiencing clinically severe psychiatric and cognitive impairments before seeking support from VETS. The participants had significantly improved, both psychiatrically and cognitively, persisting at least one month after treatment, the endpoint of the study.

“I went from being constantly angry and feeling alone, burdened by the trauma of war and the loss of 12 friends to suicide, to finding a renewed sense of hope and peace,” said Patrick Flatley, a U.S. Army Green Beret veteran and study participant. “The turning point was ibogaine treatment. Today, I am grateful to sleep well, live without daily fight or flight reactions, and look forward to life with newfound hope.”

“This reinforces what we’ve learned through thousands of treatments, that ibogaine can be safe and effective when provided in the right context. For Ambio, the study further highlights the remarkable healing potential of ibogaine, which we’re confident will expand the treatment landscape for veterans and many others,” said Jonathan Dickinson, Ambio’s CEO.

All participants in the study received treatment at Ambio Life Sciences, an independent clinic in Mexico that provides somatic therapies alongside psychedelic therapies in a medically supported environment. VETS provided travel funding for the study participants as part of its Foundational Healing Grants program, along with classes, coaching, integration support, and more. VETS does not provide psychedelic-assisted therapy.

About VETS

Founded in 2019, Veterans Exploring Treatment Solutions (VETS) is a 501(c)(3) non-profit organization working to end the veteran suicide epidemic by providing resources, research, and advocacy for U.S. military veterans seeking psychedelic-assisted therapies for traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), addiction, and other health conditions. VETS envisions a world where our veterans have access to the most advanced healthcare options to heal from the mental and physical wounds of war.

Media Contact

Brad Burge, Veterans Exploring Treatment Solutions (VETS), 1 (650)-863-6887, [email protected], vetsolutions.org 

SOURCE Veterans Exploring Treatment Solutions (VETS)

State Collection Service Celebrates Milestone 75th Anniversary


“Our family ownership model enables our team to focus on the long-term success of healthcare providers and their patients nationwide,” said Tim Haag, State’s president and chief executive officer. “We are able to provide receivables management services aligned with the provider’s goal of retaining the patient and their family for a lifetime.”

With over 700 team members today, State serves many of the nation’s largest healthcare systems. Its values remain Integrity, Excellence, Innovation, Respect, Fun, and Enthusiasm.

The company will celebrate with the State team over the next several months, including virtual and in-person special events and gift boxes shipped to each member’s home to share with their family. State’s continued trade show presence will incorporate the company’s storied past with a fun-filled theme certain to engage both clients and show attendees’ sense of fun. The celebration will also include a significant donation from the Haag family, to be announced soon.

Even as it celebrates this milestone event, State’s team is focused on continually improving the patient experience and recoveries through AI to personalize communication and payment plans as well as optimized self-service technology.

About State

State improves the financial picture for healthcare providers by delivering increased financial results while ensuring a positive patient experience. Rooted in a tradition of ethics, integrity, and innovation since 1949, State uses data analytics to drive performance and speech analytics with ongoing training to ensure patient satisfaction. A family-owned company now in its third generation of leadership, State assists healthcare organizations with services spanning the complete revenue cycle, including Pre-Service Financial Clearance, Early Out Self-Pay Resolution, Insurance Follow-Up, and Bad Debt Collection. To learn more, visit www.statecollectionservice.com.

Media Contact

Heather E Taylor, State Collection Service, 1 7657306632, [email protected], www.statecollectionservice.com

SOURCE State Collection Service

Xtalks Releases Life Science Trends to Look Out For In 2024


AI and Machine Learning — Transforming Drug Development: Artificial intelligence (AI) and machine learning (ML) are transforming life sciences research by enabling rapid and accurate analysis of massive biological data, with applications in drug discovery, disease pattern prediction and personalized treatment plans.

Jo Varshney, CEO of VeriSIM Life, told Xtalks that AI’s role in accelerating medical research and drug development will include helping improve clinical trial success rates and reducing risk by predicting drug efficacy and adverse events before a drug even enters human trials. The increasing integration of AI in drug development is also being recognized by regulatory bodies, including the US Food and Drug Administration (FDA). It’s an exciting time for AI in drug development but challenges remain in translating AI-enhanced drug candidates into clinical success.

CRISPR Gene Editing Therapeutics: CRISPR/Cas-9 gene editing technology achieved a milestone this year with the FDA’s approval of the first CRISPR-based therapy for sickle cell disease. The therapeutic, Casgevy, was jointly developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

There are a number of other companies, including Editas Medicine, Intellia Therapeutics and others co-founded by CRISPR pioneers, that are advancing CRISPR treatments for diseases such as inherited blindness and cancer. These efforts, at various stages of research and clinical trials, signal a promising future for CRISPR therapies, with more innovations and approvals anticipated in 2024.

Next Generation Health Wearables with Medical Accuracy: The global wearable medical devices market, valued at $73.77 billion in 2023, is expected to grow to $428.92 billion by 2030, driven by a focus on devices with medical relevance beyond just health and wellness. MindMics CEO Anna Barnacka, leveraging her experience as a NASA Einstein Fellow, is innovating in the field with a wireless earbud heart health monitor that uses infrasonic hemodynography for precise heartbeat measurements. She says the health wearables industry will see a trend and shift towards medically accurate wearables amid strong consumer demand for more insightful health monitoring. Additionally, the industry should start thinking about business models that have a prevention-based approach, as opposed to current treatment-based models.

Stay tuned for all of the latest trends and news in the life sciences in 2024 through our articles, video content, webinars and the Xtalks Life Science Podcast. To learn more about Xtalks’ Life Science Trends for 2024, check out Life Science Trends to Look Out for in 2024.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Ayesha Rashid
Tel: +1 (416) 977-6555 x 272
Email: [email protected]

Media Contact

Ayesha Rashid, Xtalks, +1 (416) 977-6555 x 272, [email protected], www.xtalks.com

SOURCE Xtalks

Recovery Community Organization Certification Program Launches in Washington, D.C.


This is a significant step toward creating a network of certified organizations that demonstrate a commitment to best practices and person-centered recovery.

About Faces & Voices of Recovery:

Faces & Voices of Recovery is a national organization dedicated to de-stigmatizing addiction, advocating for recovery-inclusive policies, and connecting friends, families, communities, and allies to the resources they need. Learn more at https://facesandvoicesofrecovery.org/.

Media Contact

Nicole Woodward, Faces & Voices of Recovery, 1 9493954583, [email protected], facesandvoicesofrecovery.org 

SOURCE Faces & Voices of Recovery

Sudden Cardiac Arrest Foundation Names Jayden Rodriguez Winner of the 2023 “People Saving People” Award


Amy and Jayden worked out at the same gym and had become friends. The remarkable rescue occurred at her home in Fredericksburg, Virginia. Amy had contacted Jayden, then 22, asking him to stay at her house for a while to make sure she was okay. She went to bed asking him to lock the door when he left.

Jayden sensed something was off and so he waited in the living room. Later he heard “a loud snoring noise” coming from Amy’s bedroom. He rushed there and saw that her face was turning white, her eyes were rolling back, and her lips were turning purple. He immediately called 911, lifted her off the bed, and started CPR. He continued CPR for eight minutes until EMS arrived.

After EMS took over, Jayden went above and beyond by searching social media to find her relatives and advise them of the situation.

“I have listened to the entire 911 call and am unbelievably blown away at how focused and calm he was able to remain during this terrifying situation,” said Amy.

In recognizing Jayden, Mary Newman, president of the Sudden Cardiac Arrest Foundation, said there were dozens of nominations for the award and it was challenging to select just one winner. “Everyone wins when people nearby act quickly and decisively to help victims of sudden cardiac arrest,” she said. “Reviewers, however, decided that this case best exemplified the critical importance of immediate proactive bystander action when sudden cardiac arrest occurs.”

Amy graciously accepted the award on Jayden’s behalf, sharing her experience before a large conference audience. Jayden will receive a ZOLL AED contributed by CoroMed that he may donate to a location of his choice.

About Sudden Cardiac Arrest
Sudden Cardiac Arrest is a life-threatening emergency that occurs when the heart suddenly stops beating. It strikes people of all ages who may seem to be healthy, even children and teens. When SCA happens, the person collapses and doesn’t respond or breathe normally. They may gasp or shake as if having a seizure. SCA leads to death in minutes if the person does not get help right away. Survival depends on people nearby calling 911, starting CPR, and using an automated external defibrillator, or AED (if available) as soon as possible.

About Sudden Cardiac Arrest Foundation
Sudden Cardiac Arrest Foundation is a national community benefit 501(c)(3) organization. Our vision is to eliminate preventable death and disability from sudden cardiac arrest and support people affected by SCA. Our mission is to raise awareness of SCA and promote initiatives that help save lives through education, research, and community. Sudden Cardiac Arrest Foundation is a proud sponsor of the Cardiac Arrest Survivor Alliance and proud co-sponsor of the Call-Push-Shock movement.

Media Contact

Christina Dolan, Sudden Cardiac Arrest Foundation, 407-765-0654, [email protected], https://www.sca-aware.org

SOURCE Sudden Cardiac Arrest Foundation

RCH Solutions Elevated to AWS Advanced Tier Services Partner, Expanding Expertise in Cloud Services for Life Sciences


“Attaining the AWS Advanced Tier Services Partner level marks a key development in our mission to provide highly targeted, efficient Cloud solutions to the Life Sciences sector and reflects our unwavering commitment to continuous education and improvement,” said Michael Riener, President and CEO of RCH Solutions.

Exclusively serving Life Sciences companies for over 30 years, RCH Solutions delivers specialized scientific computing solutions and services that combine scientific rigor with cross-functional IT experience. This niche IT service is particularly critical to biotech, pharmaceutical, and healthcare companies, connecting the increasingly complex worlds of research and development with technology innovation to accelerate the advancement of scientific data and novel therapeutics.

More than a testament to RCH’s understanding of Cloud technology, the achievement signals RCH’s mastery and application of Cloud strategies to meet the specialized needs of its Life Sciences customers.    

“This Advanced Tier status enables RCH to fully harness AWS’s sophisticated features, including scalable computing power essential for extensive research data analysis and application workflows, enhanced security protocols, and best practices for managing, moving, and making sense of large data sets through the power of the Cloud,” said Phil Eschallier, Chief Technology Officer at RCH. “Our customers can trust our team to continue to deliver Cloud strategies and solutions that not only meet the highest standards for technical expertise but also significantly enhance research, development, and clinical efforts as they race toward their scientific goals.”

For a deeper understanding of AWS services tiers and their qualifications, explore AWS Services Tiers; to learn more about how RCH’s AWS-focused Cloud Computing capabilities can propel your scientific endeavors, visit http://www.rchsolutions.com.

About RCH Solutions:
RCH Solutions (RCH) is a global provider of Bio-IT expertise, helping Life Sciences and Healthcare companies of all sizes clear the path to discovery. For more than 30 years, RCH has provided focused experience and unmatched specialization in designing and deploying cross-functional IT strategies, supporting R&D infrastructure, and offering workflow best practices that solve enterprise and scientific computing challenges. Learn more at http://www.rchsolutions.com.

Media Contact

Melissa Thomas, RCH Solutions, 215-499-9788, [email protected], www.rchsolutions.com

SOURCE RCH Solutions

Optimism Remains Strong on Future of Learning


Podcasts and videos were the most popular technology used in training. Half of survey respondents were currently using podcasts and videos in their training programs. Simulations and scenario-based learning were used by 49 percent of respondents.

The 2023 State of the Industry report also examined content distribution and delivery methods. Along with employee orientation and mandatory and compliance training, the training topic areas rounding out the top five included interpersonal skills (89 percent); processes, procedures, and business practices (89 percent); and managerial and supervisory training (89 percent).

The top two training delivery methods were live instructor-led traditional classrooms (92 percent) and live instructor-led virtual classrooms (82 percent). Blended learning was the least commonly used method for goods-producing industries and for healthcare and social assistance, according to the report.

Other key findings from the report include:

  • The average cost per hour of training used was $115.
  • The average number of learning hours used per employee was 20.7 in 2022, down from 32.9 in 2021.
  • Learning hours used per employee were highest for healthcare and social assistance, at 28.5 hours.
  • Half of survey respondents believed learning hours used per employee would increase in the coming months.

A free webinar on the report will take place Tuesday, December 19, at 2 p.m. ET.

About ATD

The Association for Talent Development (ATD) is the world’s largest professional membership organization supporting those who develop the knowledge and skills of employees, improve performance, and help to achieve results for the organizations they serve. Established in 1943, the association was previously known as the American Society for Training & Development (ASTD).

ATD’s members come from more than 100 countries and work in public and private organizations in every industry sector. ATD supports talent development professionals who gather locally in volunteer-led US chapters and international member networks and with international strategic partners.

For more information, visit td.org

Media Contact

Paula Ketter, Association for Talent Development, 7036838100, [email protected], td.org

SOURCE Association for Talent Development

Certainly Health Raises $2.3M in Funding to Enable Consumers to Book Any Doctor With Upfront Prices


57 percent of Americans have received a surprise bill, and 38 percent of Americans delay care for fear of the bill. Meanwhile, the cost of a healthcare service can vary by hundreds of dollars across providers with no difference in quality.

“Even with good health insurance, both my cofounder and I have received unexpected medical bills for thousands of dollars over the years,” said Kevin Chiu, Co-founder and CEO. “These personal experiences are at the core of our mission to empower healthcare consumers to book health providers without fear of the bill.”

To learn more about Certainly Health and its initiatives, please visit https://certainlyhealth.com.

About Certainly Health

Certainly Health is the only marketplace for booking medical and cosmetic care with upfront prices. Patients can compare costs and avoid surprise bills while using health insurance to book thousands of providers in NYC. Certainly also makes it easy to compare prices, provider reviews, and appointment availability across medspas for cosmetic procedures, including Botox and microneedling.

Media Contact

Kristen Mondshein, KMM Communications, 1 3058773293, [email protected]

SOURCE Certainly Health

Novel blood test helps determine efficacy and side effects of immunotherapy in lung cancer patients, AHN, Johns Hopkins Study Shows


Additionally, the research article said that blood tests that monitor the patient’s immune repertoire – that is, the specific genetic arrangements found within the patient’s T-cell receptors – help doctors to better understand the patient’s adaptive immune system, and how it will respond to an immunotherapy. Together, these “liquid biopsies” and other samples can identify a wide range of biomolecular cancer and immune system features, and as the blood tests become more sensitive, they can lead to more optimal cancer care and immunotherapies.

Immunotherapies treat diseases – typically, cancers – by activating or suppressing the immune system using certain vaccines, antibodies, or synthetic products. When activated properly, the adaptive immune system can be trained to destroy cancer cells.

“This is the future of cancer medicine – therapy regimens that are designed to match the cancer’s genetic profile and the patient’s immune system,” said Dr. Zaidi. “At the AHN Cancer Institute, we are committed to testing and developing tomorrow’s therapies, leading to more precise care and better outcomes for patients challenged by lung cancer.”

Lung cancer is the leading cause of cancer death for both men and women in the United States. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and grows more slowly than small cell lung cancer. Because small-cell cancer has often spread to the lymph nodes and elsewhere in the body by the time it’s discovered, it’s typically first treated by chemotherapy and radiation therapy.

NSCLC, meanwhile, because it’s typically confined to the lungs, is often a better candidate for surgical intervention, targeted therapy, and immunotherapy – if the cancer has the right mutations and biomarkers.
Historically, tissue biopsy is the gold standard for tumor assessment and diagnosis. However, there are risks associated with invasive sampling, particularly when it comes to fragile organs such as the lungs or brain.

But the advent of liquid biopsies – which capture circulating tumor DNA and other pertinent immune-system information – has made it easier to learn about a cancer’s genetic characteristics, to learn if a cancer has spread, or to detect important genetic alterations in the cancer. Liquid biopsies also usually have quicker turnaround times than tissue biopsies, allowing treatment to start more quickly.

“AHN has been using liquid biopsies for years to learn more about non-small cell lung cancer,” said David Bartlett, MD, Chair of the Allegheny Health Network Cancer Institute. “This paper confirms that the right blood tests, combined with the right analysis, can guide clinical decision-making and help doctors better predict clinical response to immunotherapy in lung cancer.”

The article was published in November in the American Association for Cancer Research clinical journal. Among the co-authors are David Bartlett, MD (chair of the AHN Cancer Institute), Benny Weksler, MD (system director of Thoracic Surgery at AHN), Nathan Bahary, MD (academic chief of Medical Oncology at AHN), and co-corresponding author Ali H. Zaidi, MD (medical director of Aerodigestive Research at the AHN Cancer Institute).

Dr. Zaidi was one of the paper’s co-senior/corresponding authors; researchers from Johns Hopkins Medicine, the Johns Hopkins School of Medicine, AHN, and the Sidney Kimmel Comprehensive Cancer Center also co-wrote the paper. Additionally, researchers from the Netherlands Cancer Institute, the Beaumont RCSI Cancer Centre in Ireland, and the California Institute of Technology participated in the study. The paper was supported, in part, by grants from the U.S. National Institutes of Health, and utilized blood samples from 49 AHN patients with advanced-stage (III or IV) non-small cell lung cancer.

These patient samples were provided from AHNCI Moonshot, the largest clinically annotated pan cancer biorepository in western Pennsylvania. 

Media Contact

Emily Beatty, Allegheny Health Network, 5136789620, [email protected], www.ahn.org 

SOURCE Allegheny Health Network